EFFECT OF LUTEOLIN ON OVARIAN MORPHOLOGY IN MICE WITH POLYCYSTIC OVARY SYNDROME (PCOS)

Аннотация

Polycystic ovary syndrome (PCOS) is a complex and multifactorial reproductive, endocrine and metabolic disorder with diverse clinical manifestations, covering a wide spectrum of symptoms from reproductive dysfunction to metabolic disturbances, which poses significant challenges to patients’ quality of life and health. The etiology of PCOS remains unclear and involves a complex interaction of genetics, environment and endocrine system. This makes prevention, early diagnosis and effective treatment particularly challenging. Current treatment strategies for PCOS are primarily aimed at symptomatic treatment rather than at curing the disease itself. Although existing medications such as oral contraceptives and insulin sensitizers can alleviate symptoms to some extent, their long-term use may be associated with a number of side effects such as lipid metabolism disorders and increased insulin resistance, and some patients may have a suboptimal response to therapy. Luteolin can regulate aromatase expression through the MKK3/6-p38 MAPK-CREB pathway. This study reveals a potential role for TPL2 as a novel target in estrogen biosynthesis, providing new insights for the treatment of PCOS.